Intracellular sensing of viral genomes and viral evasion

Hyun-Cheol Lee¹², Kiramage Chathuranga¹ and Jong-Soo Lee¹

Abstract
During viral infection, virus-derived cytosolic nucleic acids are recognized by host intracellular specific sensors. The efficacy of this recognition system is crucial for triggering innate host defenses, which then stimulate more specific adaptive immune responses against the virus. Recent studies show that signal transduction pathways activated by sensing proteins are positively or negatively regulated by many modulators to maintain host immune homeostasis. However, viruses have evolved several strategies to counteract/evade host immune reactions. These systems involve viral proteins that interact with host sensor proteins and prevent them from detecting the viral genome or from initiating immune signaling. In this review, we discuss key regulators of cytosolic sensor proteins and viral proteins based on experimental evidence.

Introduction
Viral infection is a major threat to human and animal health worldwide. Acute and chronic infections cause many economic and social problems. Over the past few decades, the field of molecular cell biology has contributed to our knowledge of both viruses and the host innate immune reactions that they trigger. In particular, we now understand how host cells recognize invading viruses and how the antiviral signaling cascade is regulated.

Host innate immunity is the first line of defense against viral infection. Efficient and rapid detection of invading viruses, coupled with mechanisms that distinguish viral components from host components, is a critical factor. Upon viral infection, virus-derived pathogen-associated molecular patterns (PAMPs), such as viral capsid proteins, surface glycoproteins, and the viral genome, are recognized by host pattern recognition receptors (PRRs). There are several types of PRRs, which are identified according to cellular localization and ligand specificity; these include Toll-like receptors, C-type lectin receptors, retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs), nucleotide-binding oligomerization domain (NOD)-like receptors, and cytosolic DNA sensors such as cyclic GMP-AMP synthetase¹. Sensing of viral PAMPs by PRRs triggers signaling cascades via adapter proteins such as mitochondrial antiviral signaling protein (MAVS) or stimulator of interferon genes (STING), ultimately leading to the production of host defense molecules such as type I and III interferons (IFNs), proinflammatory cytokines, and chemokines². Secreted IFNs and cytokines enhance innate immune responses via autocrine and paracrine mechanisms and induce expression of interferon-stimulated genes (ISGs) that inhibit viral replication and spread³. Secreted cytokines and chemokines are also critical for inducing effective adaptive and memory immune responses.

Nonetheless, excessive production of IFNs and prolonged inflammatory responses triggered by uncontrolled PRR signaling can have deleterious effects on the host by promoting the development of autoimmune disorders, allergies, and other immunopathologies⁴. In contrast, weak or ineffective PRR signal transduction exacerbates the severity of viral disease. Therefore, PRR-mediated signal transduction must be tightly regulated (either
positively or negatively) to maintain host immune homeostasis.

In addition, viruses have evolved several strategies to avoid detection of host antiviral immune responses; these range from interruption of viral sensors to manipulation of molecules within signaling cascades. For example, the viral genome harbors structures that mask specific molecular motifs recognized by cytosolic sensors. Some viral proteins inhibit host sensor molecules by cleaving or interfering with post-translational modifications (PTMs) of sensors. From the perspective of the virus, these actions during the early phase of invasion are critical for successful infection.

Here, we summarize recent evidence regarding interactions between key intracellular sensors, viral RNA/DNA, and molecules that regulate efficient IFN responses or maintenance of host innate immune homeostasis. Furthermore, we describe recent advances in our knowledge about viral evasion of host cytosolic sensors, focusing on interactions between cytosolic sensors and specific viral proteins.

Host viral RNA sensors and viral evasion mechanisms

Upon viral infection, the viral genome is released into the cytoplasm to initiate viral protein biosynthesis. During this step, conserved molecular structures such as triphosphates and double-stranded (ds)RNA act as PAMPs that are recognized by sensors in the host cell cytosol (Table 1). The host innate immune system includes receptors, called PRRs, that distinguish the viral genome from the host genome. To achieve this, RLRs comprising RIG-I

| PRR | Agonist | Representative virus |
|-----|---------|----------------------|
| RIG-I | 5’ ppp dsRNA | SeV, NDV, RSV, MV, VSV, IAV, EBOV, JEV, HCV, VNV, DENV, Rotavirus, Vaccinia |
|     | short dsRNA | virus, Adenovirus, Rift Valley fever virus, |
|     | 5’ ppp ssRNA | virus, Adenovirus, Rift Valley fever virus, |
|     | AU-rich 3’ UTR | Lassa virus, Nipha virus, Rabies virus, |
|     | RNase L cleavage products | Influenza B virus |
|     | Circular viral RNA | pU/UC HCV |
|     | genomic RNA | ssDNA |
| MDA5 | Long dsRNA | ECMV, MV, VNV, SeV, DENV, MHV, HCV, |
|     | RNase L cleavage products | PIUS, EV, Murine norovirus-1, Rabies virus, Saffold virus, Rotavirus, |
|     | AU-rich motifs | Adenoviruses, Theiler's virus |
| LGP2 | dsRNA | ECMV, VSV, HCV, Poliovirus |
| cGAS | RNA:DNA intermediate | dsDNA |
|     | ssDNA | ssDNA |
|     | Mitochondrial DNA | ssDNA |
| IFN-16 | dsRNA | HSV-1, HCMV, KSHV, EBV |
|     | ssDNA | ssDNA |
| AIM2 | dsDNA | MCMV, Vaccinia virus |

**Table 1 Summary of RNA and DNA viruses and ligand recognition by PRRs**

RIG-I recognizes 5’ tri- or di-phosphorylated dsRNA, the AU-rich 3’ untranslated region (UTR), RNase L cleavage products, and circular viral RNA. RIG-I detects the genomes of viruses such as vesicular stomatitis virus (VSV), influenza A virus (IAV), Sendai virus (SeV), Newcastle disease virus (NDV), respiratory syncytial virus (RSV), hepatitis C virus (HCV), and Japanese encephalitis virus (JEV). In addition, some DNA viruses such as vaccinia virus and Herpes simplex virus (HSV) and bacteria such as *Listeria monocytogenes* generate RNA that is then targeted by RIG-I. Structurally, RIG-I comprises two N-terminal caspase activation and recruitment domains (CARDs), two helicase domains (Hel-1 and Hel-2), and a C-terminal repressor domain (RD). In the resting state, RIG-I is autoinhibited by its own RD. In response to virus invasion, RIG-I recognizes viral RNA via its two components: the RD and helicase domain. The RD facilitates viral RNA recognition through its strong affinity for the 5’ end triphosphate, and the positively charged pocket structure of the RD interacts with the 5’ end of viral RNA. The helicase domain binds to dsRNA and mediates a conformational change that allows ATP binding to activate RIG-I. This conformational change...
opens up the CARDs, which are essential for downstream signaling\(^\text{14,17}\). During this step, RIG-I is activated or inactivated by several regulators and/or PTMs (see below). Open CARDs interact with the CARD MAVS to activate downstream signaling cascades\(^\text{18}\). In addition, adapters such as TNF receptor associated factor (TRAF) 3 or TRAF6, serine/threonine-protein kinases, TANK-binding kinase (TBK1), and I\(\kappa\)B kinase (IKK) are activated\(^\text{9,10}\). Consequently, transcription factors such as IRF3, IRF7, and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-\(\kappa\)B) trigger production of type I IFNs and induce expression of antiviral molecules\(^\text{9,10}\).

RIG-I is essential for innate antiviral immunity; however, it is modulated by several regulatory molecules to protect against viral spread or the maintenance of host immune homeostasis (Fig. 1). First, RIG-I activation or inactivation is regulated by PTMs such as ubiquitination, phosphorylation, and acetylation\(^\text{9}\). During activation, RIG-I undergoes K63-linked ubiquitination by RING finger protein 135 (RNF135/Riplet), tripartite motif-containing protein (TRIM4), and TRIM25\(^\text{19–23}\). Importantly, K63-linked ubiquitination of the CARD at K172 is mediated by TRIM25, which induces RIG-I oligomerization\(^\text{22}\). Caspase 12 promotes K63-mediated ubiquitination of RIG-I via TRIM25 to promote RIG-mediated signaling, whereas linear ubiquitin chain assembly complex (LUBAC) negatively regulates TRIM25 via K48-linked ubiquitination to trigger proteasomal degradation\(^\text{24,25}\).

Conversely, ubiquitin carboxyl-terminal hydrolase (USP) 15 mediates deubiquitination of I\(\kappa\)B\(\alpha\) via the cytosolic kinases I\(\kappa\)B\(\alpha\) and TBK1/IKK\(\alpha\), respectively. Activated transcription factors NF-\(\kappa\)B, IRF7 and IRF3 translocate to the nucleus and induce transcription of type I IFN and pro-inflammatory genes.

---

**Fig. 1 Regulators and interacting viral proteins of the RLR-MAVS antiviral signaling pathway.** Schematic presentation of positive and negative regulators of RLRs (Top) and melanoma differentiation-associated protein-5 (MDAS) (Bottom) through PTMs or non-PTMs and immune invasion viral proteins interacting with RIG-I (Top) and MDAS (Bottom). The RLR-MAVS pathway includes the key cytosolic sensors RIG-I and MDAS, which detect viral RNA. These sensors subsequently interact with the central antiviral signaling protein MAVS, which in turn activates the transcription factors NF-\(\kappa\)B and IRF3/IRF7 via the cytosolic kinases IKK and TBK1/IKK\(\varepsilon\), respectively. Activated transcription factors NF-\(\kappa\)B, IRF7 and IRF3 translocate to the nucleus and induce transcription of type I IFN and pro-inflammatory genes.
granules, which generate a platform complex for viral sensing and signaling. In contrast to activation by K63-linked ubiquitination, removal of K63-linked poly-ubiquitin by the deubiquitinating enzyme CYLD negatively regulates RIG-I activity. Two other deubiquitinases, USP3 and USP21, also negatively control RIG-I activity in the same way. K63-linked ubiquitination of RIG-I by TRIM25, MEX3C, and TRIM4 and deubiquitination of RIG-I by CYLD, USP3, and USP21 occur in the CARDs, whereas K63-linked ubiquitination by the RNF135/Riplet occurs in the RD (K788), which has a positive effect on TRIM25-mediated K63-linked ubiquitination in the CARDs. In contrast, K48-linked ubiquitination serves as a signal for proteasomal degradation of RIG-I. RNF122 and RNF125 mediate K48-linked ubiquitination, which inhibits RIG-I-mediated antiviral innate immune responses. Sialic acid binding Ig-like lectin G (Siglec-G) recruits the E3 ligase c-cbl to RIG-I, resulting in degradation via K48-linked ubiquitination. The deubiquitinase USP4 also serves as a negative regulator of ubiquitination.

Phosphorylation and acetylation are also important PTMs involved in RIG-I regulation. In resting cells, for example, RIG-I is autoinhibited by phosphorylation and acetylation. Phosphorylation on the CARDs of RIG-I is maintained by protein kinase C (PKC) α/β and removed by protein phosphatase 1 (PP1) α/γ, which induces further K63-linked ubiquitination at this domain. Casein kinase II (CK2) phosphorylates the RD of RIG-I, and removal of this phosphorylation allows for K63-linked ubiquitination via RNF135. When RIG-I is inactivated, the RD domain is acetylated. In the presence of RNA ligands, histone deacetylase (HDAC) 6 deacetylates the RD and allows RIG-I to bind to viral RNA to promote oligomerization. However, some regulators involved in RIG-I function do not act via PTMs. As a positive regulator, the shorter isoform of PARP-13 (ZAPS) associates with RIG-I and promotes its oligomerization, whereas IRF1 functions to increase expression of RIG-I. The mitochondrial targeting chaperone protein 14-3-3ε interacts with RIG-I, thereby translocating it to the translocon. As a negative regulator, RNF123 blocks RIG-I and inhibits signaling of MAVS without its E3 ligase function. Caspase-8 is recruited to RIG-I upon viral infection, whereupon it cleaves the RIG-I signaling enhancer receptor-interacting protein (RIP) 1. Other molecules that negatively regulate RIG-I are listed in Table 2.

RIG-I is tightly controlled by a wide range of regulatory factors. For structural activation and initiation of innate immune responses, RIG-I is involved in many specific modification mechanisms with other regulatory factors. Since the discovery that TRIM25 activates RIG-I via K63 ubiquitination, a burgeoning number of other factors regulating RIG-1 activity, such as PTMs, oligomerization, RNA recognition, relocation, and stabilization, have been identified. Moreover, beyond these processes directly affecting RIG-1 activity, some of the factors that regulate RIG-1 are controlled by other factors. Taken together, these findings highlight the complexity and delicate control of RIG-I-mediated innate immune signaling.

**Viral evasion of RIG-I-mediated responses**

In the early stage of viral infection, avoidance of innate immunity, including the interferon response, is important for successful viral infection. Because RIG-I is a key viral RNA sensor that initiates rapidly innate immune responses, it is targeted by diverse viral proteins.

Many viruses possess proteins that interfere directly with RIG-I. For example, HSV-1 tegument protein US11 interacts with RIG-I to block formation of the RIG-I-MAVS complex; porcine deltacoronavirus (PDCoV) accessory protein NS6 interferes with RIG-I binding to dsRNA. The 3C protease of Enterovirus (EV) 71, Poliovirus, Echovirus, Rhinovirus type 16, Rhinovirus type 1A, and Encephalomyocarditis virus (EMCV) cleaves and inactivates RIG-I. Latent membrane protein (LMP) 1 of Epstein–Barr virus (EBV) mediates proteasomal degradation of RIG-I, and the nonstructural (NS) protein of severe fever with thrombocytopenia syndrome virus (SFTSV) hijacks RIG-I and its signaling proteins in the cytoplasmic structure. In addition, evidence suggests that human respiratory syncytial virus (HRSV) N and P proteins colocalize with RIG-I and that the influenza virus NS1 protein interacts with RIG-I directly. Interaction between RIG-I and these viral proteins mainly leads to direct functional impairment of RIG-I. The processes used by these viral proteins include cleavage, degradation, suspension, and inhibition of RIG-I. Specific viral proteins also interfere with RIG-I activation. A number of viral proteins target TRIM25-mediated K63-linked ubiquitination of RIG-I. The NS1 protein of IAV targets TRIM25 to block K63-linked ubiquitination, whereas Paramyxovirus V proteins, HRSV NS1, and the severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein target TRIM25 to inhibit activation of RIG-I. Moreover, the human papillomavirus (HPV) E6 protein increases the activity of USP15 to promote proteasomal degradation of TRIM25, and Herpesvirus mediate autoubiquitination of TRIM25 to prevent K63-linked ubiquitination of RIG-I. Furthermore, West Nile virus (WNV) NS1 interferes with the innate immune response by mediating proteasomal degradation of RIG-I and inhibiting K63-linked ubiquitination. In addition, some viral proteins dephosphorylate RIG-I and inhibit its signaling, and measles virus (MV) activates the C-type lectin DC-SIGN and blocks PP1 activity to attenuate RIG-I in...
The viral proteins that interact with or affect RIG-I are listed in Table 2.

Table 2: Regulators for RNA and DNA virus PRRs

| PRR | Classification | Regulator | Function | Ref. |
|-----|----------------|-----------|----------|------|
| RIG-I | PTMs Positive | TRIM4 | K63 ubiquitination | 23 |
| RIG-I | PTMs Positive | TRIM25 | K63 ubiquitination | 20 |
| RIG-I | PTMs Positive | RNF135/Riplet/REUL | K63 ubiquitination | 17-19 |
| RIG-I | PTMs Positive | Ube2D3/Ube2N | K63 ubiquitination | 126 |
| RIG-I | PTMs Positive | Cyclophilin A | TRIM25-mediated ubiquitination | 127 |
| RIG-I | PTMs Positive | MEX3C | K63 ubiquitination | 25 |
| RIG-I | PTMs Positive | USP15 | Antiviral stress granule | 24 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | HDAC6 | Deacetylation | 36,37 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | Caspase 12 | TRIM25-mediated ubiquitination | 23 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | USP4 | Deubiquitination | 32 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | PP1α/γ | Dephosphorylation | 34 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | WHIP-TRIM14-PPP6C | Dephosphorylation | 128 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | c-Src | TRIM25 phosphorylation | 129 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | TRIM38 | SUMOylation | 59 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | PP1α/γ | Dephosphorylation | 34 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | TRIM65 | K63 ubiquitination | 61 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | ARRDC4 | TRIM65 mediated ubiquitination | 149 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | RNF125 | K27, K48 ubiquitination | 139 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | USP3 | Deubiquitination | 27 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | RIOK3 | Phosphorylation | 63 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | CgAS | PTMs Positive | PI(4,5)P2 | Plasma membrane localization | 92 |
| taken together, results to date show that viruses express specific proteins that interfere with RIG-I | | AIM2 | Non-PTMs Positive | PI(4,5)P2 | Physical interaction plasma membrane localization | 92 |

Table 2 continued

| PRR | Classification | Regulator | Function | Ref. |
|-----|----------------|-----------|----------|------|
| MDAS | PTMs Positive | PAI2B | SUMOylation | 90 |
| MDAS | PTMs Positive | PP1α/γ | Dephosphorylation | 34 |
| MDAS | PTMs Positive | TRIM65 | K63 ubiquitination | 61 |
| MDAS | PTMs Positive | ARRDC4 | TRIM65 mediated ubiquitination | 149 |
| MDAS | Non-PTMs Positive | TRIM40 | K27, K48 ubiquitination | 139 |
| MDAS | Non-PTMs Positive | USP3 | Deubiquitination | 27 |
| MDAS | Non-PTMs Positive | RIOK3 | Phosphorylation | 63 |
| MDAS | Non-PTMs Positive | 14-3-3η | Oligomerization Intracellular redistribution | 150 |
| MDAS | Non-PTMs Positive | DDX6 | Physical interaction | 74 |
| MDAS | Non-PTMs Positive | PUM1 | Physical interaction | 74 |
| MDAS | Non-PTMs Positive | TRIM56 | Monoubiquitination | 87 |
| MDAS | Non-PTMs Positive | USP14 | Physical interaction | 60 |
| MDAS | Non-PTMs Positive | SENP2 | DeSUMOylation | 88 |
| MDAS | Non-PTMs Positive | HDAC3 | Deacetylation | 91 |
| MDAS | Non-PTMs Positive | G3BP1 | Monoglutamylation | 99 |
| MDAS | Non-PTMs Positive | SENP2 | DeSUMOylation | 88 |
| MDAS | Non-PTMs Positive | Akt | Phosphorylation | 91 |
| MDAS | Non-PTMs Positive | G3BP1 | Changing the structure Oligomerization | 94 |
| MDAS | Non-PTMs Positive | ZCCHC3 | Physical interaction | 95 |
| AIM2 | Non-PTMs Positive | NLRP3 | Physical interaction | 96 |
| AIM2 | Non-PTMs Positive | Beclin-1 | Physical interaction | 96 |
| AIM2 | Non-PTMs Positive | AIM2 | Autophagic degradation | 120 |
| AIM2 | Non-PTMs Negative | TRIM11 and p62 | Autophagic degradation | 120 |

Taken together, results to date show that viruses express specific proteins that interfere with RIG-I.
function via diverse mechanisms and are essential for viral pathogenesis.

**MDA5 and viral evasion**

MDA5 is a major intracellular sensor that recognizes viral dsRNA, including the genomes of EMCV, Poliovirus, Coxackievirus, Rotavirus, Dengue virus (DENV), WNV, and murine hepatitis virus10,11 (Table 3). MDA5 recognizes long dsRNA, AU-rich motifs, and RNase L cleavage products10,11,60. MDA5 activation is similar to that of RIG-I; however, the MDA5 RD binds to the RNA backbone and not to the 5′ end. This difference allows the HEL2 loop of MDA5 to insert into the major groove of viral RNA, which is not limited to the RNA end16. This interaction triggers the two CARDs to form a tetrameric structure that transduces a signal to the adapter molecule MAVS, which is shared with the RIG-I-mediated pathway16,61.

Several regulators and PTMs also regulate MDA5 activation and inactivation (Fig. 1). MDA5 activation involves dephosphorylation of S88 on the MDA5 CARD by PP1α/γ36. MDA5 also undergoes SUMOylation by PIAS2β, which promotes interferon signaling62, and TRIM38 acts as a SUMO E3 ligase to mediate downstream signaling via SUMOylation of K43/K865 of MDA563. K63-linked ubiquitination at the CARDs is also a critical mechanism underlying MDA5 activation. In addition, TRIM65 mediates K63-linked ubiquitination of K743 in the CTD of MDA5 to induce MDA5 oligomerization and activation64, and DDX60 also acts as a positive regulator by binding to MDA565. In contrast, right open reading frame 3 (RIOK) phosphorylates the RD of MDA5 at S828 to inhibit filament formation66. Notably, the E3 ubiquitin ligase RNF125 negatively regulates MDA5 via its ligase function, whereas RNF123 performs the same role independently of its ligase function31,43. USP3 and USP21 inhibit MDA5 function via deubiquitination17, and proteins such as dihydroxyacetone kinase (DAK), Atg5-Atg12, NLRC5, and TRIM13 interact with and inhibit MDA5 (Table 2)63,67–69.

MDA5 is also subject to several types of activation that resemble those that activate RIG-I. Indeed, PP1α/γ, USP3, RNF123, and TRIM40 target RIG-I and

### Table 3 Viral evasion mechanism for RNA and DNA virus PRRs

| PRR | Virus | Virulence factor | Function | Ref. |
|-----|-------|-----------------|----------|-----|
| RIG-I | IAV | N51 | TRIM25 inhibition | 30 |
| Picornavirus, Poliovirus, Rhinovirus, EMCV | 3Cpro | Cleavage | 45 |
| CVB | 3Cpro | Cleavage | 69 |
| SFTSV | N5s | Physical interaction | 46 |
| MERS-CoV | 4A | PACT suppression | 156 |
| EBOV | VP35 | Physical interaction | 157 |
| Marburg Virus | | | |
| SARS-CoV | N | TRIM25 inhibition | 51 |
| EBV | BPLF1 | TRIM25 autoubiquitination, RIG-I signalosome inactivation | 158 |
| RSV | N51 | TRIM25 inhibition | 52 |
| Paramyxovirus | V | Physical interaction | 53 |
| PDCoV | N56 | Physical interaction | 44 |
| HPV | E6 | USP15 activation | 54 |
| Toscana virus | N5s | Proteasomal degradation | 159 |
| FMDV | Lpro | Cleavage | 160 |
| HBV | 2B | Expression level decreasing | 162 |
| HCV | NS3-4A | Cleavage of Ripl | 64 |
| HCV | US11 | Physical interaction | 43 |
| HRSV | N | Physical interaction | 48 |
| CVA | 3C | Physical interaction | 168 |
| EV | | | |
| PDCoV | N56 | Physical interaction | 44 |
| ECV | 2C | Physical interaction | 169 |
| EV71 | 3Dpol | Physical interaction | 170 |
| LGP2 | FMDV | Lpro | Cleavage | 80 |
| cGAS | V Protein | Suppress interaction with MDA5 | 26 |
| cGAS | SHIV | ORF52 (Ki6GAS) | Disrupts cGAS binding to DNA | 103 |
| | | LANA | Physical interaction | 103 |
| ZIKV | NS1 | Cleave K11 polyubiquitin chains from capase-1 | 98 |
| HSV | UL37 | Deamidation of cGAS | 99 |
| HCMV | UL31 | Enzyme activity inhibition | 102 |
| | | Disassociation DNA from cGAS | 102 |
| | | pUL83 | Direct binding, interference with cGAS STING binding | 101 |
| DENV | NS5B | Degradation | 104 |
| HIV-1 | Capsid | Sensing inhibition | 171 |
| IFN-1 | SHIV | Lytic proteins, Ubiquitination and proteasomal degradation | 112 |

### Table 3 continued

| PRR | Virus | Virulence factor | Function | Ref. |
|-----|-------|-----------------|----------|-----|
| HSV | ICPO, ICPR | Proteasomal degradation | 163 |
| HCMV | pUL97 | Proliferation | 172 |
| | | Mis-localization | |
| | | Trafficking into multivesicular bodies | 115 |
| | | pUL83 | Direct binding, block oligomerization, Physical interaction | 118,119 |
| AIP2 | HCMV | pUL83 | Physical interaction | 121 |
| HSV | VP22 | Block AIP2 oligomerization | 122 |
MDA5 simultaneously, likely because the domain structures of these two proteins are similar. Upon activation, these two proteins transmit signals through their CARDs to MAVS and share subsequent pathways involved in cytokine secretion. Hence, these two proteins are commonly involved in virus recognition and play a complementary role in the initiation of innate immunity. Regardless, further studies on the molecular mechanisms that regulate MDA5 activation and inactivation are necessary.

Different viral proteins have been reported to inhibit MDA5. The V proteins of paramyxoviruses limit the induction of IFN-β by interfering with MDA5 but not RIG-I75. In addition, the V protein of Parainfluenza virus (PIV) 5, Mumps virus, MV, Menangle virus, Hendra virus, Nipah virus, Maquera virus, SeV, and Salem virus binds to MDA570. In particular, structural studies have demonstrated that the V protein of PIV5 recognizes a structural motif within MDA5, thereby disrupting its ATP-hydrolysis function as well as filament formation71. The helicase C domain of MDA5 is sufficient for association with V proteins from PIV2, PIV5, MV, Mumps virus, Hendra virus, and Nipah virus. In addition, human herpesvirus tegument protein US11 and the HRSV N protein antagonize innate immune responses initiated by MDA545,50. The 2A protease of Coxsackievirus B (CVB) 3 and Poliovirus mediates degradation of MDA5 in a proteasome- and caspase-dependent manner, whereas EV 71 2A cleaves MDA5 to inactivate it72.

**LGP2 and viral evasion**

LGP2 is an RLR that lacks N-terminal CARDs, and thus LGP2 cannot transmit signals to MAVS; however, it can bind to viral RNA and modulate the activities of RIG-I and MDA571. Overall, the exact role of LGP2 in innate immunity is still unclear, though based on previous studies, LGP2 is a negative regulator of RLRs73,74 and acts synergistically with MDA563,64. Although recent evidence shows that LGP2 strengthens MDA5-mediated innate immune responses against HCV infection75, other studies suggest that LGP2 acts as a negative regulator by interacting with TRAF family proteins and interfering with their ubiquitin ligase activity76.

Because LGP2 lacks CARDs and signaling activity, few studies have examined how it is regulated. Nonetheless, research suggests that pumilio protein 1 (PUM1) regulates expression of innate immune genes by acting as a biphasic negative regulator of LGP276. In addition, PACT amplifies innate immune responses when expressed together with both LGP2 and MDA578.

Although the role of LGP2 is not clear, interactions between viruses and LGP2 have been reported. For example, the Paramyxovirus V protein interacts with LGP2 and interferes with its ability to coactivate MDA579. Foot and mouth disease virus (FMDV) 2B also directly interacts with LGP2, and expression of LGP is decreased by the C-terminal region of 2B80. Furthermore, FMDV leader protease (Lpro) directly interacts with and cleaves LGP280; this event is thought to affect the function of LGP2 that regulates MDA5, which is responsible for FMDV genome recognition. Further research will be required to address the functions or molecular mechanisms of LGP2 and how its activity is affected by viral proteins.

**Host viral DNA sensors and viral evasion mechanisms**

Upon DNA virus invasion, viral DNA is released into the host cell cytoplasm, and viral protein synthesis begins. Because the DNA of eukaryotic cells is located in the nucleus or mitochondrion, the presence of viral DNA in the cytoplasm acts as a PAMP, which is detected by several intracellular sensor molecules.81

Based on recent reports, cytoplasmic viral DNA is recognized by cyclic GMP-AMP synthase (cGAS), interferon gamma inducible protein 16 (IFI16), interferon-inducible protein (AIM2), DDX41, and RNA PolIII, among others. Similar to detection of viral RNA, immediate detection of viral DNA triggers host innate immune responses and enhances expression of antiviral-related cytokines.74,81,82. cGAS and IFI16 transmit signals to the endoplasmic reticulum (ER) adapter protein STING, whereas AIM2 and IFI16 mediate activation of the inflammasome.82,83 Ultimately, these reactions activate type I IFN signaling and antiviral responses, similar to those observed in RLR signaling. The activities of DNA-sensing factors are also modulated by a number of positive and negative regulators. However, DNA viruses have evolved numerous and elaborate strategies to counteract viral DNA sensing by host sensor molecules. Below, we summarize the regulation of major sensor factors and viral evasion mechanisms.

**cGAS and viral evasion**

cGAS is a well-known cytosolic DNA sensor essential for early innate immune responses to DNA viruses. In the cytoplasm, cGAS detects self and nonself DNA and induces production of type I IFNs and proinflammatory cytokines. Ligands for cGAS are present in the genomes of HSV-1, Kaposi’s sarcoma-associated herpesvirus (KSHV), Vaccinia virus, murine gammaherpesvirus 68 (MHV68), Adenovirus, and Hepatitis B virus (HBV).18,74,82 cGAS binds to the sugar-phosphate backbone of dsDNA without sequence specificity. This interaction is mediated by positively charged DNA-binding sites of cGAS and induces a conformational change in cGAS, opening activation sites for cGAMP synthesis18,82. After recognition of viral DNA, cGAS generates 2′,3′-cGAMP, along with ATP and GTP, all of which play roles as second messengers to...
cGAS as a cosensor to enable recognition of dsDNA. Recent studies have also reported glutamylation and beclin 1 targets cGAS to suppress cGAMP family (OASL) protein downregulates cGAS enzyme mediated cleavage of cGAS. Oligoadenylate-synthetase-activating it and protecting it from degradation. cGAS is also controlled by PTMs, such as phosphorylation, ubiquitination, SUMOylation, acetylation, and glutamylation. cGAS is mediated by E3 ligase, TRIM14, RINCK/TRIM41, and TRIM56, whereas ER-resident RNF185 catalyzes K27-linked ubiquitination in response to HSV-1 infection. Importantly, RNF185-mediated ubiquitination at K173 and K384, two major ubiquitination sites, activates cGAS, thus generating more cGAMP. RINCK/TRIM41 and TRIM56 mediate cGAS monoubiquitination and promote innate immune responses to DNA viruses; cGAS K335 is also monoubiquitinated by TRIM56 and E1 and UbCH5 E2 enzymes.

K48-linked ubiquitination of cGAS is a recognition signal that triggers selective autophagic degradation, whereby TRIM14 recruits USP14 to cleave K48-linked ubiquitination and stabilize cGAS. SUMOylation also plays an important role in regulating cGAS. TRIM38 mediates SUMOylation of cGAS to inhibit its degradation, whereas sentrin-specific protease (SENP) 2 induces SUMOylation and ultimately degradation of cGAS. SENP7 targets cGAS for deSUMOylation, thereby stabilizing it and protecting it from degradation. cGAS is also regulated by glutamylation, phosphorylation, and acetylation. Tubulin tyrosine ligase-like (TTLLs) glutamylases 4 and 6 target E302 for monoglutamylation and E272 for polyglutamylation, respectively, whereas cytosolic carboxypeptidases (CCP) 5 and 6 antagonize TTLLs. Phosphorylation of cGAS at S305 and S291, as catalyzed by protein kinase B (PKB/Akt), strongly suppresses cGAS. In addition, acetylation inhibits cGAS-mediated production of interferon. There are also other mechanisms of cGAS regulation that do not rely on PTMs. As positive regulators, manganese and the Ras-GAP SH3 domain-binding protein (G3BP1) target cGAS to promote its DNA-binding activity; PI(4,5) P2 localizes cGAS to the plasma membrane. The CCHC-type zinc-finger (ZF) protein ZCCHC3 acts with cGAS as a cosensor to enable recognition of dsDNA.

In contrast, inflammasome activation triggers caspase-mediated cleavage of cGAS. Oligoadenylate-synthetase-family (OASL) protein downregulates cGAS enzyme activity, and decline 1 targets cGAS to suppress cGAMP synthesis. Recent studies have also reported glutamylation and monoubiquitination as novel PTMs of cGAS, and two novel carboxypeptidases and glutamylases regulate cGAS via differential glutamylation. TRIM56 monoubiquitinates cGAS and affects antiviral signaling by promoting a marked increase in cGAS dimerization and DNA-binding activity, which eventually increases cGAMP production.

To antagonize host innate immune activation, Zika virus (ZIKV) NS1 stabilizes caspase 1 and protects it from proteasomal degradation. K11-linked ubiquitin chains of caspase 1 at K134 are cleaved by USP8, which is recruited by NS1. Thus, ZIKV triggers degradation of cGAS by caspase 1, thereby blocking antiviral innate immunity. HSV-1 also evades cGAS-mediated innate immune responses through two viral proteins: the UL37 tegument protein deamidates cGAS, a process that determines species-specific inactivation of HSV-1; and VP22 of HSV-1 interacts with cGAS to inhibit its enzymatic activity.

To evade cGAS-mediated innate immune responses, UL31 of human cytomegalovirus (HCMV) interacts with cGAS to inhibit cGAMP synthesis; this is achieved by preventing cGAS from binding to DNA, whereas pp65 of HCMV inhibits cGAS activity. ORF52 and LANA of KSHV also inhibit cGAS activity. LANA of KSHV interacts with cGAS directly to inhibit cGAS-mediated pathways, whereas ORF52 of KSHV prevents cGAS from sensing DNA by inhibiting its enzymatic activity. In addition, cGAS detects mitochondrial DNA released during DENV infection; however, the NS2B of DENV mediates lysosomal degradation of cGAS.

The mechanisms by which virus proteins interfere with cGAS involve inhibition of DNA-binding activity and enzymatic activity or degradation. In particular, HSV-1 and HCMV express multiple proteins that interfere with cGAS-triggered innate immunity. It is thought that many viruses have evolved diverse mechanisms that hinder cGAS function because cGAS is an intracellular sensor that is critical for detecting viral DNA. cGAS is inhibited not only by DNA viruses but also by RNA viruses such as ZIKV and DENV. Moreover, DNA as a byproduct of RNA viral infection is recognized by cGAS, and viruses possess a mechanism to avoid this type of recognition. Taken together, these findings suggest that viral pathogenesis involving host immunity is more complex and sophisticated than previously thought, indicating that more research is needed in this area.

**IFI16 and viral evasion**

IFI16 is a nuclear protein located predominantly in the nucleus; however, it shuttles between the nucleus and cytoplasm to sense viral DNA derived from Herpesvirus, human immunodeficiency virus (HIV), and bacteria such as listeria monocytogenes. IFI16 contains an N-terminal pyrin domain (PYD) and two C-terminal HIN domains: it recognizes viral DNA via the HIN domain and then interacts with cGAS to promote cGAMP production and plays a vital role in cGAMP-mediated signaling.
which activates TBK1 within the STING complex5,108. IFI16 is also able to detect viral DNA in the nucleus, activating ASC, an adapter molecule for the inflammasome and leading to production of IL-1β and IL-18109,110.

As IFI16 recognizes the Herpesvirus genome, it has been the subject of intense study. Upon Herpesvirus infection, IFI16 is acetylated by P300 in the nucleus and activates STING after its translocation to the cytoplasm111. cGAS also stabilizes IFI16 to promote innate immune signaling during HSV infection, though cGAS generates less cGAMP112. BRCA1 forms a complex with IFI16 in the nucleus that is strengthened upon viral infection; this triggers translocation of IFI16 to the cytoplasm and inflammasome activation113. In contrast, DNA viruses produce specific proteins that enable escape from IFI16-mediated immune responses. The HSV-1 viral E3 ubiquitin ligase ICP0 suppresses IFI16 by mediating its proteasomal degradation114. In addition, it has been reported that KSHV lytic protein(s) potentially degrade IFI16 to maintain latency115. Finally, HCMV possesses proteins that interfere with IFI16; Vps4 and TGN46 induce trafficking of IFI16 to multivesicular bodies, whereas pUL83 interacts with the PYRIN domain, which interferes with DNA sensing or inhibits expression of interferon-inducible genes116–118.

To date, few studies have been conducted on viral proteins that interfere with the recognition and signaling mechanisms of IFI16. However, as mentioned above, recent papers suggest the existence of a relationship between IFI16 and cGAS-cGAMP signaling112,119. A study in keratinocytes showed that IFI16 is required for STING activation by cGAMP and that IFI16 interacts with the cGAS–STING pathway in macrophages112. These findings indicate that IFI16 is more closely related to DNA virus recognition and viral defense mechanisms than once thought. For this reason, it is expected that new virus proteins that interfere with the recognition and signaling mechanisms of IFI16 will be reported in the near future.

**AIM2 and viral evasion**

AIM2, a member of the PYRIN protein family, consists of two domains: the PYRIN domain at the N-terminus and HIN200 domain at the C-terminus81. The HIN200 domain is responsible for DNA binding, whereas the
PYRIN domain interacts with the PYRIN domain of ASC to activate caspase-1\(^{174,81}\). AIM2 has affinity for viral DNA derived from murine cytomegalovirus (MCMV) and Vaccinia virus; activation of AIM2 leads to secretion of IL-1β of IL-18 and mediates inflammation in response to viral infection\(^{15,81}\). As regulatory molecules, nuclear factor E2-related factor-2 (Nrf2) and pyruvate kinase isozyme M2 (PKM2) act as positive regulators of AIM2 inflammasome activation\(^{120,121}\). In contrast, high-mobility group box 1 (HMGB1) and DNA complexes induce autophagy to reduce activation of the AIM2 inflammasome\(^{122}\). TRIM11 mediates autophagy-dependent autophagosome formation and IL-1β secretion; p62 and p47 inhibit inflammasome assembly and negatively regulates AIM2 mediated in cell death\(^{123}\).

In contrast, pUL83 of HCMV binds to AIM2 and disrupts AIM2-mediated inflammasome activation. Upon HCMV infection, pUL83 interacts with AIM2 in macrophages, thereby inhibiting activated inflammasome components\(^{124}\). Recent reports show that VP22 of HSV-1 negatively regulates AIM2 inflammasome formation and IL-1β secretion: VP22 interacts with the HIN200 domain, but not with the PYRIN domain, to inhibit oligomerization of AIM2. Consequently, VP22-mediated inactivation of the inflammasome promotes virus replication in vivo\(^{125}\).

Taken together, these studies indicate that the AIM2 inflammasome serves as a key element in innate immunity against DNA viruses and that several viral proteins specifically inhibit AIM2 activation. Because the AIM2 inflammasome is also involved in the sensing of other DNA viruses, it is expected that further research will identify even more viral proteins that interact with AIM2. Furthermore, inflammasome activation not only constitutes a barrier to DNA viral infection but also is injurious to the host. In this respect, further studies are needed to determine the mechanisms that modulate the activity of the AIM2 inflammasome to enhance our understanding of host responses to DNA viral infection.

**Conclusions**

Intracellular sensing of viral RNA or DNA by PRRs is indispensable for host cells to mount an antiviral innate immune response to inhibit replication and spread of invading viruses and prime an effective adaptive immune response\(^{18,73}\). This review summarizes our current knowledge of the key intracellular sensors and how they are modulated by various molecules to mediate IFN responses and the maintenance of immune homeostasis. Moreover, we discuss viral proteins that interact with these host cytosolic sensing molecules and facilitate evasion of host defenses.

Over the past decade, our understanding of intracellular sensor-mediated antiviral responses has expanded, and we know much more about the molecular mechanisms by which they are regulated via host and viral factors. This knowledge not only allows us to understand viral pathogenesis but also reveals how intracellular sensors are activated and regulated. Extensive knowledge of these mechanisms will allow for research and development of novel anti-inflammatory agents, immunostimulatory agents, new vaccines, and antiviral agents that target cellular regulators or specific viral proteins. Regardless, further work is needed to identify other cytosolic sensors (such as novel sensors of nucleic acids), other positive or negative regulatory molecules and related pathways, and novel escape mechanisms utilized by new viruses or variants.

**Acknowledgements**

This work was supported by the National Research Foundation (Grant No. 2018M3A9H4079660, 2018M3A9H4078703, 2019R1A2C2008283), Republic of Korea.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Publisher’s note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Received**: 25 March 2019 **Revised**: 15 May 2019 **Accepted**: 22 May 2019. Published online: 11 December 2019

**References**

1. Goubau, D., Deddouche, S. & Reis e Sousa, C. Cytosolic sensing of viruses. *Immunity* 38, 855–869 (2013).
2. Takeuchi, O. & Akira, S. Pattern recognition receptors and inflammation. *Cell* 140, 805–820 (2010).
3. Ishikawa, L. B. & Donlin, L. T. Regulation of type I interferon responses. *Nat. Rev. Immunol.* 14, 36–49 (2014).
4. Mogensen, T. H. Pathogen recognition and inflammatory signaling in innate immune defenses. *Curr. Microbiol.* 22, 240–273 (2009). Table of Contents.
5. Chiang, C. & Gack, M. U. Post-translational control of intracellular pathogen sensing pathways. *Trends Immunol.* 38, 39–52 (2017).
6. Chan, Y. K. & Gack, M. U. Viral evasion of intracellular DNA and RNA sensing. *Nat. Rev. Microbiol.* 14, 360–373 (2016).
7. Hur, S. Double-stranded RNA sensors and modulators in innate immunity. *Annu. Rev. Immunol.* 39, 349–375 (2019).
8. Luo, Y. M. & Gale, M. Jr. Immune signaling by RIG-I-like receptors. *Immunity* 34, 680–692 (2011).
9. Chen, N. et al. RNA sensors of the innate immune system and their detection of pathogens. *IUBMB Life* 69, 297–304 (2017).
10. Said, E. A., Tremblay, N., Al-Balushi, M. S., Al-Jabri, A. A. & Lamarre, D. Viruses seen by our cells: the role of viral RNA sensors. *Curr. Opin. Immunol.* 30, 201–207 (2017).
11. Chow, K. T., Gale, M. Jr. & Luo, Y. M. RIG-I and other RNA sensors in antiviral immunity. *Annu. Rev. Immunol.* 36, 667–694 (2018).
12. Chaalal, M. et al. RIG-I recognizes the 5’ region of dengue and zika virus genomes. *Cell Rep.* 24, 320–328 (2018).
13. Hagmann, C. A. et al. RIG-I detects triphosphorylated RNA of Listeria monocytogenes during infection in non-immune cells. *PLoS ONE* 8, e62872 (2013).
14. Luo, D. et al. Structural insights into RNA recognition by RIG-I. *Cell* 147, 409–422 (2011).
15. Leung, D. W. & Amarasinghe, G. K. Structural insights into RNA recognition and activation of RIG-I-like receptors. *Curr. Opin. Struct. Biol.* 22, 297–308 (2012).
16. Luo, D. Toward a crystal-clear view of the viral RNA sensing and response by RIG-I-like receptors. *RNA Biol.* 11, 25–32 (2014).
38. Choi, S. J. et al. HDAC6 regulates cellular viral RNA sensing by deacetylation
39. Liu, H. M. et al. Regulation of retinoic acid inducible gene-I (RIG-I) activation
29. Cui, J. et al. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I.
37. Sun, Z., Ren, H., Liu, Y., Teeling, J. L. & Gu, J. Phosphorylation of RIG-I by casein
27. Kuniyoshi, K. et al. Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in
26. Pauli, E. K. et al. The ubiquitin-specific protein kinase C (PKC)-alpha and PKC-beta negatively regulate RIG-I antiviral signal activation.
35. Maharaj, N. P., Wies, E., Stoll, A. & Gack, M. U. Conventional protein kinase C-
24. Inn, K. S. et al. Linear ubiquitin assembly complex negatively regulates RIG-I-
23. Yan, J., Li, Q., Mao, A. P., Hu, M. M. & Shu, H. B. TRIM25 regulates type I interferon induction and cellular antiviral response by targeting RIG-I for K63-linked ubiquitination.
34. Inn, K. S. et al. Linear ubiquitin assembly complex negatively regulates RIG-I-mediated antiviral activity.
22. Gack, M. U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.
19. Gao, D. et al. REUL is a novel E3 ubiquitin ligase and stimulator of retinoic acid-inducible gene-I.
18. Ori, D., Murase, M. & Kawai, T. Cytosolic nucleic acid sensors and innate immune responses.
43. Wang, S. et al. RNF123 has an E3 ligase-independent function in RIG-I-like receptor-mediated antiviral signaling by deubiquitylating TRIM25.
21. Oshiumi, H., Miyashita, M., Matsumoto, M. & Seya, T. A distinct role of Riplet in targeting RIG-I CARDs to mediate RIG-I degradation.

References

17. Takahasi, K. et al. Non-self RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune responses.
18. Ori, D., Murase, M. & Kawai, T. Cytosolic nucleic acid sensors and innate immune regulation.
19. Gao, D. et al. REUL is a novel E3 ubiquitin ligase and stimulator of retinoic acid-inducible gene-I.
20. Oshiumi, H., Matsumoto, M., Hatakeyama, S. & Seya, T. R qP3 poly(A) is a selective RING finger protein, ubiquitinates RIG-I to promote interferon-beta induction through deubiquitination and stabilization of RIG-I.
21. Oshiumi, H., Miyashita, M., Matsumoto, M. & Seya, T. A distinct role of Riplet in targeting RIG-I CARDs to mediate RIG-I degradation.
22. Gack, M. U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-mediated antiviral activity.
23. Yan, J., Li, Q., Mao, A. P., Hu, M. M. & Shu, H. B. TRIM25 regulates type I interferon induction and cellular antiviral response by targeting RIG-I for K63-linked ubiquitination.
24. Inn, K. S. et al. Linear ubiquitin assembly complex negatively regulates RIG-I-mediated type I interferon induction.
25. Pauli, E. K. et al. The ubiquitin-specific protein kinase C (PKC)-alpha and PKC-beta negatively regulate RIG-I antiviral signal activation.
26. Pauli, E. K. et al. The ubiquitin-specific protein kinase C (PKC)-alpha and PKC-beta negatively regulate RIG-I antiviral signal activation.
27. Kuniyoshi, K. et al. Pivotal role of RNA-binding E3 ubiquitin ligase MEX3C in RIG-I-mediated antiviral innate immunity.
28. Wang, J. et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase.
29. Cui, J. et al. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors.
30. Fan, Y. et al. USP21 negatively regulates antiviral response by acting as a RIG-I deubiquitinase.
31. Aitamoto, K. et al. Negative regulation of the RIG-I signaling by the ubiquitin ligase RNF125.
32. Gu, J. et al. USP3 inhibits type I interferon signaling by deubiquitinating RIG-I-like receptors.
33. Feng, P. et al. Porcine deltacoronavirus accessory protein NS6 antagonizes interferon beta production by interfering with the binding of RIG-I/MDA5 to double-stranded RNA.
34. Jiang, X., Wang, S., Lin, R., Mossmann, K. L. & Zheng, C. Herpes simplex virus 1 tegument protein US11 downmodulates the RLR signaling pathway via direct interaction with RIG-I and MDA5.
35. Maharaj, N. P., Wies, E., Stoll, A. & Gack, M. U. Conventional protein kinase C-
36. Santiago, F. W. et al. Hijacking of RIG-I signaling proteins into virus-induced cytoplasmic structures correlates with the inhibition of type I interferon responses.
37. Sun, Z., Ren, H., Liu, Y., Teeling, J. L. & Gu, J. Phosphorylation of RIG-I by casein kinase II inhibits its antiviral response.
38. Cho, S. J. et al. HDAC6 regulates cellular viral RNA sensing by deacetylation of RIG-I.
39. Liu, H. M. et al. Regulation of retinoic acid inducible gene-I (RIG-I) activation by the histone deacetylase 6. Eukliae Medicine 9, 195–206 (2016).
40. Su, Z. Z., Sarkar, D., Emdad, L., Baral, P. M. & Fisher, P. B. Central role of interferon regulatory factor-1 (IRF-1) in controlling retinoic acid inducible gene-I (RIG-I) expression.
41. Hayakawa, S. et al. ZAP5 is a potent stimulator of signaling mediated by the RNA helicase RIG-I during antiviral responses.
42. Liu, H. M. et al. The mitochondrial targeting chaperone 14-3-3-Sepin regulates a RIG-I translocon that mediates membrane association and innate antiviral immunity.
43. Wang, S. et al. RNF123 has an E3 ligase-independent function in RIG-I-like receptor-mediated antiviral signaling.
44. Rajabi, A. et al. RIG-I RNA helicase activation of IRF3 transcription factor is negatively regulated by caspase-8-mediated cleavage of the RPA1 protein.
71. Parisien, J. P. et al. A shared interface mediates paramyxovirus interference with antiviral RNA helicases MDAS and LGP2. J. Virol. 83, 7252–7260 (2009).
72. Feng, Q. et al. Enterovirus 2Apro targets MDAS and MAVS in infected cells. J. Virol. 88, 3369–3378 (2014).
73. Radoshevich, L. & Dussurget, O. Cytosolic innate immune sensing and signaling upon infection. Front. Microbiol. 7, 313 (2016).
74. McFadden, M. J., Gokhale, N. S. & Horner, S. M. Protect this house: cytosolic sensing of viruses. Curr. Opin. Virol. 22, 36–43 (2017).
75. Hei, L. & Zhong, J. Laboratory of genetics and physiology 2 (LGP2) plays an essential role in hepatitis C virus infection-induced interferon responses. Hepatology 65, 1478–1491 (2017).
76. Parisien, J. P. et al. cGAS produces a 2′–5′-linked cyclic dinucleotide second messenger that activates STING during DNA virus infection to limit interferon responses. Proc. Natl Acad. Sci. USA 114, E6902–E6911 (2017).
77. Liu, Y., Qu, L., Rozman, B. & Zhou, G. G. PUM1i sabi phase negative regulatory innate immune sensor LGP2 disrupts MDA5 signaling enhancement but is not relevant to LGP2-mediated RLR signaling inhibition. J. Virol. 88, 18180–18188 (2014).
78. Rodriguez, K. R. & Horvath, C. M. Paramyxovirus V protein interaction with the antiviral sensor LGP2 disrupts MDAS signaling enhancement but is not relevant to LGP2-mediated RLR signaling inhibition. J. Virol. 88, 18180–18188 (2014).
79. Zhu, Z. et al. Foot-and-mouth disease virus infection inhibits LGP2 protein expression by a mechanism involving apoptosis, inflammation, and autophagy. Autophagy 13, 1449–1459 (2017).
80. Liu, Z. S. et al. RINCK-mediated monoubiquitination of cGAS promotes DNA sensing of cGAS to mediate immune evasion. Cell Host Microbe 24, 69–80 e64 (2018).
81. Zhang, G. et al. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proc. Natl Acad. Sci. USA 113, E1034–E1043 (2016).
82. Aguime, S. et al. Dengue virus NS2B protein targets cGAS for degradation and promotes mitochondrial DNA sensing during infection. Nat. Microbiol. 2, 17037 (2017).
83. Unterholzer, L. et al. IFI16 is an innate immune sensor for intracellular DNA. Nat. Immunol. 11, 997–1004 (2010).
84. Duan, X. et al. Differential roles for the interferon-inducible IFI16 and AIM2 innate immune sensors for cytosolic DNA in cellular senescence of human fibroblasts. Mol. Cancer Res. 9, 590–602 (2011).
85. Hu, M. M. et al. Sumoylation promotes the stability of the DNA sensor cGAS in the presence of interferon. Cell Death Dis. 10, e1007148 (2019).
86. Zheng, Y. et al. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspinase-1 axis. EMBO J. 37, e99347 (2018).
87. Zhang, J. et al. Species-specific deamidation of cGAS by herpes simplex virus UL37 protein facilitates viral replication. Cell Host Microbe 24, 234–248 e235 (2018).
88. Huang, J. et al. Herpes simplex virus 1 tegument protein VP22 abrogates cGAS/STING-mediated antiviral innate immunity. J. Virol. 92, e00841–e18 (2018).
89. Bolatti, M. et al. Human cytomegalovirus tegument protein pp65 (pUL83) dampens type I interferon production by inactivating the DNA sensor cGAS without affecting STING. J. Virol. 92, e01774–17 (2018).
90. Zhang, Z. F. et al. Human cytomegalovirus protein UL31 inhibits DNA sensing of cGAS to mediate immune evasion. Cell Host Microbe 24, 69–80 e64 (2018).
91. Zhang, G. et al. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proc. Natl Acad. Sci. USA 113, E1034–E1043 (2016).
92. Aguime, S. et al. Dengue virus NS2B protein targets cGAS for degradation and promotes mitochondrial DNA sensing during infection. Nat. Microbiol. 2, 17037 (2017).
93. Kim, S. H. et al. Innate immune DNA sensors cGAS and APOBEC3G regulate DNA binding and function of the cGAS-STING pathway. Mol. Cell 54, 289–296 (2014).
94. Chen, M. et al. TRIM14 inhibits cGAS degradation mediated by selective autophagy receptor p62 to promote innate immune responses. Mol. Cell 64, 105–119 (2016).
95. Wang, Q. et al. The E3 ubiquitin ligase RNF185 facilitates the cGAS-mediated innate immune response. PLoS Pathog. 13, e1006284 (2017).
96. Liu, Z. et al. cGAS-mediated DNA sensing by the antiviral sensor LGP2 regulates innate immune responses. Cell Res. 28, 337–338 (2017).
97. Ren, G. J. et al. TRIM65-mediated monocubiquitination of cGAS promotes antiviral innate immune responses. Cell Biol. 8, 35 (2018).
98. Hu, M. M. et al. Sumoylation promotes the stability of the DNA sensor cGAS and the adaptor STING to regulate the kinetics of response to DNA Virus. Immunity 45, 555–568 (2016).
99. Cui, Y. et al. SENP7 potentiates cGAS activation by relieving SUMO-mediated inhibition of cytosolic DNA sensing. PLoS Pathog. 13, e1006156 (2017).
100. Xia, P. et al. Glutamylation of the DNA sensor cGAS regulates its binding and synthesis activity in antiviral immunity. Nat. Immunol. 17, 369–378 (2016).
101. Zheng, Y. et al. Zika virus elicits inflammation to evade antiviral response by cleaving cGAS via NS1-caspinase-1 axis. EMBO J. 37, e99347 (2018).
102. Zhang, J. et al. Species-specific deamidation of cGAS by herpes simplex virus UL37 protein facilitates viral replication. Cell Host Microbe 24, 234–248 e235 (2018).
103. Huang, J. et al. Herpes simplex virus 1 tegument protein VP22 abrogates cGAS/STING-mediated antiviral innate immunity. J. Virol. 92, e00841–e18 (2018).
104. Bolatti, M. et al. Human cytomegalovirus tegument protein pp65 (pUL83) dampens type I interferon production by inactivating the DNA sensor cGAS without affecting STING. J. Virol. 92, e01774–17 (2018).
105. Zhang, Z. F. et al. Human cytomegalovirus protein UL31 inhibits DNA sensing of cGAS to mediate immune evasion. Cell Host Microbe 24, 69–80 e64 (2018).
106. Zhang, G. et al. Cytoplasmic isoforms of Kaposi sarcoma herpesvirus LANA recruit and antagonize the innate immune DNA sensor cGAS. Proc. Natl Acad. Sci. USA 113, E1034–E1043 (2016).
126. Shi, Y. et al. Ube2D3 and Ube2N are essential for RIG-I-mediated MAVS aggregation in antiviral innate immunity. Nat. Commun. 8, 15138 (2017).
127. Liu, W. et al. Cytoplasmic A-regulated ubiquitination is critical for RIG-I-mediated antiviral immune responses. Cell 166, e24425 (2017).
128. Tan, P. et al. Assembly of the WIIH-TRIM14-PPP4C mitochondrial complex promotes RIG-I-mediated antiviral signaling. Mol. Cell 68, 293–307.e5 (2017).
129. Lee, N. R., Choi, J. Y., Yoon, I. H., Lee, J. K. & Inn, K. S. Positive regulatory role of c-Src-mediated TRIM25 tyrosine phosphorylation on RIG-I ubiquitination and RIG-I-mediated antiviral signaling pathway. Cell Immunol. 332, 94–100 (2018).
130. Hu, M. M., Liao, C. Y., Yang, Q., Xie, X. Q. & Shu, H. B. Innate immunity to RNA virus is regulated by temporal and reversible sumoylation of RIG-I and MDAS. J. Exp. Med 214, 973–989 (2017).
131. Zhao, K. et al. Cytoplasmic STAT4 promotes antiviral type I IFN production by blocking CHIP-mediated degradation of RIG-I. J. Immunol. 196, 1209–1217 (2016).
132. Li, H. et al. USP14 promotes K63-linked RIG-I deubiquitination and suppresses antiviral immune responses. Eur. J. Immunol. 49, 42–53 (2019).
133. Zhou, P. et al. MLL5 suppresses antiviral innate immune response by facilitating STUB1-mediated RIG-I degradation. Sci. Rep. 9, 1243 (2018).
134. Zhao, C. et al. The E3 ubiquitin ligase TRIM40 attenuates antiviral innate immunity via facilitating MDA5 oligomerization and intracellular redistribution. PLoS Pathog. 15, e1007582 (2019).
135. Willemsen, J. et al. Phosphorylation-dependent feedback inhibition of RIG-I by DAPK1 identified by Kinome-wide siRNA Screening. Mol. Cell 65, 403–415 e408 (2017).
136. Kim, S. S., Sze, L. & Lam, K. P. The stress granule protein G3BP1 binds viral RNA binding protein La/SS-B promotes RIG-I-mediated type I and type III IFN induction of antiviral signaling. Sci. Rep. 7, 23377 (2016).
137. Liu, W. et al. Cyclophilin A-regulated ubiquitination is critical for RIG-I–MDAS mediated antiviral signaling. Cell Death Dis. 7, e2110 (2016).
138. Lian, H. et al. The zinc-chelating compound 1,2-bis(2-aminoethyl)glycerol (BEG) promotes ubiquitination of RIG-I by targeting MDA5 and RIG-I mediated antiviral signaling pathway. Cell Biol. 130, 1531–1543 (2017).
139. Nunez, R. D. et al. The RNA helicase DDX6 associates with RIG-I to augment influenza virus to antagonize innate immunity. J. Virol. 87, 1087–1094 (2013).
140. Mahony, R., Broadbent, L., Maier-Moore, J. S., Power, U. F. & Jefferies, C. A. The RNA-binding protein La/SS-B promotes RIG-I-mediated antiviral signaling. PLoS Pathog. 14, e1007582 (2019).
141. Lin, J. P., Fan, Y. K. & Liu, H. M. The 14-3-3eta chaperone protein promotes antiviral innate immunity by facilitating MDAS oligomerization and intra-cellular redistribution. PLoS Pathog. 15, e1007582 (2019).
142. Zhu, Q. et al. DHX29 functions as an RNA co-sensor for MDAS-mediated EMCV-specific antiviral immunity. PLoS Pathog. 14, e1006886 (2018).
143. MacDuff, D. A. et al. HDL1 is essential for the induction of type I and III interferons by MDAS and regulates persistent murine noroviral infection. J. Virol. 92, e01386–18 (2018).
144. Li, L. F. et al. Interferon-inducible oligoadenylate synthetase-like protein acts as an antiviral effector against classical swine fever virus via the MDAS-mediated type I interferon-signaling pathway. J. Virol. 91, e01514–16 (2017).
145. Diao, F. et al. Negative regulation of MDAS– but not RIG-I-mediated innate antiviral signaling by the dihydroxyacetone kinase. Proc. Natl Acad. Sci. USA 104, 11706–11711 (2007).
146. Kral, Y. et al. Negative regulation of melanoma differentiation-associated gene 5 (MDAS)-dependent antiviral innate immune responses by Arf-like protein SB. J. Biol. Chem. 290, 1269–1280 (2015).
147. Siu, K. L. et al. Middle ear respiratory syndrome coronavirus 4a protein is a double-stranded RNA-binding protein that suppresses PACT-induced activation of RIG-I and MDAS in the innate antiviral response. J. Virol. 88, 5666–5672 (2014).
148. Edwards, M. R. et al. Differential regulation of interferon responses by ebola and marburg virus VP35 proteins. Cell Rep. 14, 1632–1640 (2016).
149. Gupta, S. et al. Herpesvirus deconjugates inhibit the IFN response by promoting TRIM25 autoubiquitination and functional inactivation of the RIG-I signalingosome. PLoS Pathog. 14, e1007652 (2018).
150. Gori-Savellini, G., Valentini, M. & Cusi, M. G. Toscana virus NS5 protein inhibits the induction of type I interferon by interacting with RIG-I. J. Virol. 87, 6660–6667 (2013).
151. Wang, D. et al. The leader proteinase of foot-and-mouth disease virus negatively regulates the type I interferon pathway by acting as a viral deubiquitase. J. Virol. 85, 3758–3766 (2011).
152. Li, D. et al. Foot-and-mouth disease virus non-structural protein 3A inhibits the interferon-beta signaling pathway. Sci. Rep. 6, 21888 (2016).
153. Zhu, Z. et al. Foot-and-mouth disease virus viroporin 2B antagonizes RIG-I–Mediated Antiviral Effects by Inhibition of Its Protein Expression. J. Virol. 90, 11106–11121 (2016).
154. Hou, Z. et al. Hepatitis B virus inhibits intrinsic RIG-I and RIG-G immune signaling via inducing miR146a. Sci. Rep. 6, 21650 (2016).
155. Oshumi, H., Miyashita, M., Matsumoto, M. & Seya, T. A distinct role of Riplet-mediated K63-Linked polyubiquitination of the RIG-I represor domain in human antiviral innate immune responses. PLoS Pathog. 9, e1003533 (2013).
156. Zhao, J. et al. A viral deamidase targets the helicase domain of RIG-I to block RNA-induced activation. Cell Host Microbe 20, 770–784 (2016).
157. Manokaran, G. et al. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science 350, 217–221 (2015).
158. Chan, Y. K. & Gack, M. U. A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity. Nat. Immunol. 17, 523–530 (2016).
159. Rui, Y. et al. Disruption of MDAS-mediated innate immune responses by the 3C proteins of cowpea mosaic virus 16, cowpea mosaic virus 16 and enterovirus 68. J. Virol. 91, e00546–17 (2017).
160. Li, L. et al. Encephalomyocarditis virus 2C protein antagonizes interferon-beta signaling pathway through interaction with MDAS. Antivir. Res. 161, 70–84 (2019).
161. Kuo, R. L. et al. Role of enteroviral RNA-dependent RNA polymerase in regulation of MDAS-mediated interferon-beta activation. J. Virol. 93, e00132–16 (2019).
162. Manokaran, G. et al. Dengue subgenomic RNA binds TRIM25 to inhibit interferon expression for epidemiological fitness. Science 350, 217–221 (2015).
163. Chan, Y. K. & Gack, M. U. A phosphomimetic-based mechanism of dengue virus to antagonize innate immunity. Nat. Immunol. 17, 523–530 (2016).
164. Rui, Y. et al. Disruption of MDAS-mediated innate immune responses by the 3C proteins of cowpea mosaic virus 16, cowpea mosaic virus 16 and enterovirus 68. J. Virol. 91, e00546–17 (2017).
165. Li, L. et al. Encephalomyocarditis virus 2C protein antagonizes interferon-beta signaling pathway through interaction with MDAS. Antivir. Res. 161, 70–84 (2019).
166. Kuo, R. L. et al. Role of enteroviral RNA-dependent RNA polymerase in regulation of MDAS-mediated interferon-beta activation. J. Virol. 93, e00132–16 (2019).
167. Lahaye, X. et al. The capsids of H1V-1 and H1V-2 determine immune detection of the viral cDNA by the innate sensor cEGs in dendritic cells. Immunol. 99, 1132–1142 (2013).
168. Dell’Oste, V. et al. Innate nuclear sensor IFI16 translocates into the cytoplasm during the early stage of in vitro human cytomegaloviral infection and is entrapped in the egressing virions during the late stage. J. Virol. 88, 6970–6982 (2014).